DUSA Pharmaceuticals Inc. Board of Directors Under Investigation for Potential Breaches of Fiduciary Duty by Law Offices of

  DUSA Pharmaceuticals Inc. Board of Directors Under Investigation for
  Potential Breaches of Fiduciary Duty by Law Offices of Howard G. Smith

Business Wire

BENSALEM, Pa. -- November 13, 2012

Law Offices of Howard G. Smith announces that it is investigating potential
claims against the Board of Directors of DUSA Pharmaceuticals Inc. (“DUSA” or
the “Company”) (Nasdaq: DUSA) related to the proposed acquisition of the
Company by Sun Pharmaceutical Industries Ltd. The transaction is valued at
approximately $230 million or $8.00 per share.

This investigation concerns whether the Board of Directors of DUSA breached
their fiduciary duties to stockholders by failing to adequately shop the
Company before agreeing to enter into the proposed transaction, and whether
the Company has disclosed all material information to shareholders about the
transaction. The Company has seen substantial recent growth. Its share price
skyrocketed from $4.89 on June 19, 2012 to $7.00 on October 16, 2012. Further,
at least one analyst has set a target price for the Company’s stock at $9.50.

If you are a shareholder of DUSA, if you have information or would like to
learn more about our investigation, or if you wish to discuss these matters or
have any questions concerning this announcement or your rights or interests
with respect to these matters, please contact Howard G. Smith, Esquire, of Law
Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem,
Pennsylvania 19020 by telephone at 215-638-4847, Toll-Free at 888-638-4847, or
by email to howardsmith@howardsmithlaw.com, or visit our website at
http://www.howardsmithlaw.com.

Contact:

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847 or Toll-Free: 888-638-4847
howardsmith@howardsmithlaw.com
http://www.howardsmithlaw.com
 
Press spacebar to pause and continue. Press esc to stop.